FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3026647502> ?p ?o ?g. }

• W3026647502 abstract "Abstract Background Pirfenidone (PFD) is effective for pulmonary fibrosis (PF), but its action mechanism has not been fully explained. This study explored the signaling pathways involved in anti-fibrosis role of PFD, thus laying a foundation for clinical application. Methods Pulmonary fibrosis mice models were constructed by bleomycin (BLM), and TGF-β1 was used to treat human fetal lung fibroblasts (HLFs). Then, PFD was added into treated mice and cells alone or in combination with β-catenin vector. The pathological changes, inflammatory factors levels, and Collagen I levels in mice lung tissues were assessed, as well as the activity of HLFs was measured. Levels of indices related to extracellular matrix, epithelial-mesenchymal transition (EMT), Wnt/GSK-3β/β-catenin and TGF-β1/Smad2/3 signaling pathways were determined in tissues or cells. Results After treatment with BLM, the inflammatory reaction and extracellular matrix deposition in mice lung tissues were serious, which were alleviated by PFD and aggravated by the addition of β-catenin. In HLFs, PFD reduced the activity of HLFs induced by TGF-β1, inhibited levels of vimentin and N-cadherin and promoted levels of E-cadherin, whereas β-catenin produced the opposite effects to PFD. In both tissues and cells, Wnt/GSK-3β/β-catenin and TGF-β1/Smad2/3 signaling pathways were activated, which could be suppressed by PFD. Conclusions PFD alleviated pulmonary fibrosis in vitro and in vivo through regulating Wnt/GSK-3β/β-catenin and TGF-β1/Smad2/3 signaling pathways, which might further improve the action mechanism of anti-fibrosis effect of PFD." @default.
• W3026647502 created "2020-05-29" @default.
• W3026647502 creator A5004807635 @default.
• W3026647502 creator A5057301071 @default.
• W3026647502 creator A5058902371 @default.
• W3026647502 creator A5063862279 @default.
• W3026647502 creator A5070879896 @default.
• W3026647502 creator A5089328820 @default.
• W3026647502 date "2020-05-24" @default.
• W3026647502 modified "2023-10-16" @default.
• W3026647502 title "Pirfenidone alleviates pulmonary fibrosis in vitro and in vivo through regulating Wnt/GSK-3β/β-catenin and TGF-β1/Smad2/3 signaling pathways" @default.
• W3026647502 cites W1547000965 @default.
• W3026647502 cites W1975318062 @default.
• W3026647502 cites W2021943078 @default.
• W3026647502 cites W2022275011 @default.
• W3026647502 cites W2042006898 @default.
• W3026647502 cites W2059114286 @default.
• W3026647502 cites W2116163278 @default.
• W3026647502 cites W2123901563 @default.
• W3026647502 cites W2146916955 @default.
• W3026647502 cites W2174254940 @default.
• W3026647502 cites W2229205184 @default.
• W3026647502 cites W2320839002 @default.
• W3026647502 cites W2342679639 @default.
• W3026647502 cites W2409779133 @default.
• W3026647502 cites W2417598373 @default.
• W3026647502 cites W2484335322 @default.
• W3026647502 cites W2512377627 @default.
• W3026647502 cites W2564229868 @default.
• W3026647502 cites W2577820901 @default.
• W3026647502 cites W2580660536 @default.
• W3026647502 cites W2591068902 @default.
• W3026647502 cites W2594583498 @default.
• W3026647502 cites W2597078743 @default.
• W3026647502 cites W2599075603 @default.
• W3026647502 cites W2614775927 @default.
• W3026647502 cites W2737138474 @default.
• W3026647502 cites W2783076904 @default.
• W3026647502 cites W2801120540 @default.
• W3026647502 cites W2887387122 @default.
• W3026647502 cites W2898101483 @default.
• W3026647502 cites W2951968919 @default.
• W3026647502 doi "https://doi.org/10.1186/s10020-020-00173-3" @default.
• W3026647502 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7245944" @default.
• W3026647502 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32448163" @default.
• W3026647502 hasPublicationYear "2020" @default.
• W3026647502 type Work @default.
• W3026647502 sameAs 3026647502 @default.
• W3026647502 citedByCount "54" @default.
• W3026647502 countsByYear W30266475022020 @default.
• W3026647502 countsByYear W30266475022021 @default.
• W3026647502 countsByYear W30266475022022 @default.
• W3026647502 countsByYear W30266475022023 @default.
• W3026647502 crossrefType "journal-article" @default.
• W3026647502 hasAuthorship W3026647502A5004807635 @default.
• W3026647502 hasAuthorship W3026647502A5057301071 @default.
• W3026647502 hasAuthorship W3026647502A5058902371 @default.
• W3026647502 hasAuthorship W3026647502A5063862279 @default.
• W3026647502 hasAuthorship W3026647502A5070879896 @default.
• W3026647502 hasAuthorship W3026647502A5089328820 @default.
• W3026647502 hasBestOaLocation W30266475021 @default.
• W3026647502 hasConcept C121608353 @default.
• W3026647502 hasConcept C126322002 @default.
• W3026647502 hasConcept C137620995 @default.
• W3026647502 hasConcept C189165786 @default.
• W3026647502 hasConcept C2776232574 @default.
• W3026647502 hasConcept C2776694085 @default.
• W3026647502 hasConcept C2777714996 @default.
• W3026647502 hasConcept C2778341716 @default.
• W3026647502 hasConcept C2779013556 @default.
• W3026647502 hasConcept C2779832356 @default.
• W3026647502 hasConcept C2780559512 @default.
• W3026647502 hasConcept C2781244666 @default.
• W3026647502 hasConcept C502942594 @default.
• W3026647502 hasConcept C62478195 @default.
• W3026647502 hasConcept C71924100 @default.
• W3026647502 hasConcept C76419328 @default.
• W3026647502 hasConcept C86803240 @default.
• W3026647502 hasConcept C95444343 @default.
• W3026647502 hasConceptScore W3026647502C121608353 @default.
• W3026647502 hasConceptScore W3026647502C126322002 @default.
• W3026647502 hasConceptScore W3026647502C137620995 @default.
• W3026647502 hasConceptScore W3026647502C189165786 @default.
• W3026647502 hasConceptScore W3026647502C2776232574 @default.
• W3026647502 hasConceptScore W3026647502C2776694085 @default.
• W3026647502 hasConceptScore W3026647502C2777714996 @default.
• W3026647502 hasConceptScore W3026647502C2778341716 @default.
• W3026647502 hasConceptScore W3026647502C2779013556 @default.
• W3026647502 hasConceptScore W3026647502C2779832356 @default.
• W3026647502 hasConceptScore W3026647502C2780559512 @default.
• W3026647502 hasConceptScore W3026647502C2781244666 @default.
• W3026647502 hasConceptScore W3026647502C502942594 @default.
• W3026647502 hasConceptScore W3026647502C62478195 @default.
• W3026647502 hasConceptScore W3026647502C71924100 @default.
• W3026647502 hasConceptScore W3026647502C76419328 @default.
• W3026647502 hasConceptScore W3026647502C86803240 @default.
• W3026647502 hasConceptScore W3026647502C95444343 @default.
• W3026647502 hasIssue "1" @default.
• W3026647502 hasLocation W30266475021 @default.
• W3026647502 hasLocation W30266475022 @default.

• next